DeutschNewstral
Article
Mmarketwatch.com on 2022-09-28 13:29
Regulatory approval is next: Mizuho lifts Biogen to buy on news of Alzheimer's drug success as shares soar2 min read
Related news
- WAlzheimer's drug from Biogen, partner receives FDA approvalwraltechwire.com
In reversal, Biogen to file for approval of Alzheimer's drugbizjournals.com- Biogen, Eisai to push for fast FDA approval for second Alzheimer's drugbizjournals.com
- The Petri Dish: Biogen seeks accelerated approval for second Alzheimer's drugbizjournals.com
- BA Third Expert Quits FDA Panel Over Approval of Biogen Alzheimer's Drug 2 minbarrons.com
- MBiogen and Eisai make plans to take another Alzheimer's drug to the FDA3 min readmarketwatch.com
- BFDA Will Weigh Full Approval for Alzheimer's Drug. Why It Matters for Biogen Stock. 3 min readbarrons.com
- BBiogen Says EU Regulator Takes 'Negative Opinion' on Its Alzheimer's Drug1 min readbarrons.com
Biogen reanalyzes studies, presses ahead on Alzheimer's druglasvegassun.com- FBiogen to seek Alzheimer’s drug approvalft.com
Biogen to cease production of controversial Alzheimer's drugPOLITICO
Biogen And Eisai Present Positive Results For Experimental Alzheimer's DrugForbes
Biogen trial drug shows promise in fight against Alzheimer'sThe Japan Times- Biogen pays California biotech $350M upfront for Alzheimer's gene therapybizjournals.com
- Biogen analysts pounce on 'thin' Alzheimer's trial databizjournals.com
- Biogen doubles down on Alzheimer's with new collaboration dealbizjournals.com
- Biogen touts ‘resilience’ but gives little guidance on Alzheimer's drugbizjournals.com
- Biogen lays out plans for confirmatory study of Alzheimer's drugbizjournals.com